These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28670136)

  • 1. Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions.
    D'Elia JA; Segal AR; Bayliss GP; Weinrauch LA
    Int J Nephrol Renovasc Dis; 2017; 10():153-158. PubMed ID: 28670136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
    Blau JE; Tella SH; Taylor SI; Rother KI
    Diabetes Metab Res Rev; 2017 Nov; 33(8):. PubMed ID: 28736981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.
    John M; Gopinath D; Jagesh R
    Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Lopez JM; Macomson B; Ektare V; Patel D; Botteman M
    Am Health Drug Benefits; 2015 Sep; 8(6):309-18. PubMed ID: 26557225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.
    Mohammad H; Borja-Hart N
    J Pharm Technol; 2018 Aug; 34(4):144-148. PubMed ID: 34860970
    [No Abstract]   [Full Text] [Related]  

  • 8. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
    Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
    Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
    Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports.
    Juneja D; Nasa P; Jain R; Singh O
    World J Diabetes; 2023 Aug; 14(8):1314-1322. PubMed ID: 37664476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
    Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
    Diaz-Ramos A; Eilbert W; Marquez D
    Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.
    Pujara S; Ioachimescu A
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617710040. PubMed ID: 28589154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports.
    Altowayan WM
    Ann Med Surg (Lond); 2022 Dec; 84():104879. PubMed ID: 36582864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.